User-Fee Bill Advances With Broad Support, Additional Device Reforms

The US Senate Health, Education, Labor, and Pensions Committee approved the FDA Reauthorization Act, reauthorizing drug and device user fees and multiple additions device regulation reforms, on a 21-2 vote. The mark-up session also gave HELP members from both parties a chance to vent about provisions they'd want to see in a Senate version of an Affordable Care Act repeal bill.

The Senate HELP Committee agreed May 11, on a 14-2 vote, to move user-fee reauthorization legislation to the Senate floor.

The FDA Reauthorization Act (FDARA) that would enact the MDUFA IV user-fee agreement, and put into place an array of previously introduced, additional reforms related to device facility inspections, accessories,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.